Church & Dwight (CHD) Q2 EPS Beats 9%

Core Insights - Church & Dwight reported Q2 2025 earnings per share of $0.94 (Non-GAAP), exceeding analyst expectations of $0.86 and its own guidance of $0.85 adjusted EPS [1][5] - Net sales (GAAP) reached $1,506.3 million, surpassing estimates by $19.1 million but down 0.3% year-over-year [1][5] - The company faces challenges with gross margin tightening and underperformance in certain product categories, particularly vitamins [1][7] Financial Performance - Non-GAAP EPS for Q2 2025 was $0.94, a 1.1% increase from $0.93 in Q2 2024 [2] - GAAP revenue was $1,506.3 million, a slight decrease of 0.3% from $1,511.2 million in Q2 2024 [2] - Organic sales growth was minimal at 0.1%, with domestic organic sales declining by 1.0% while international sales grew by 4.8% [2][6] Business Strategy - The company focuses on "power brands" that contribute approximately 70% of net sales and profits, including laundry detergent and vitamins [3] - Recent strategies include acquisitions, international expansion, and optimizing brand mix, while also pruning underperforming businesses [4] - The vitamin segment is under review for potential restructuring or divestment due to ongoing underperformance [11] Market Dynamics - Five out of seven power brands gained market share, with HERO, ARM & HAMMER, and THERABREATH identified as key growth drivers [9] - The newly acquired Touchland brand has become the eighth power brand, contributing to growth [10] - E-commerce sales accounted for 23% of total consumer sales, up from 22% in Q2 2024 [10] Operational Challenges - Gross margin decreased to 45.0% (Non-GAAP), down 0.4 percentage points from the previous year, impacted by rising manufacturing costs and tariffs [2][7] - The company incurred approximately $51 million in pre-tax charges related to exits from underperforming businesses [8] - Cash from operations fell by $83.4 million to $416.5 million due to working capital changes and lower operating earnings [13] Future Outlook - For fiscal 2025, management expects net sales and organic sales growth in the range of 0% to 2%, with adjusted EPS also projected to rise by 0% to 2% [14] - Q3 2025 guidance anticipates reported and organic sales growth of 1% to 2%, but adjusted EPS is expected to decline to $0.72, a 9% decrease from the prior year [15] - Strategic decisions regarding the vitamin business are expected by the end of fiscal 2025 [15]